PTC Therapeutics Sees $2 Billion-Plus Sephience Potential, Sets January Guidance Date

PTC Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • PTC Therapeutics sees Sephience as a potential $2 billion-plus opportunity, but CEO Matt Klein said that is not official guidance and will take time to achieve. The company plans to issue 2027 sales guidance in January and expects continued U.S. growth.
  • About a year after launch, Sephience was being used by more than 2,000 patients worldwide, with availability expected in over 20 countries by year-end. PTC estimates a potential market of 58,000 patients across the U.S. and other accessible markets.
  • PTC reported $182 million in third-quarter revenue and more than $2.1 billion in cash, and remains on track to reach cash-flow break-even in 2026. International growth is expected to build in 2027 as the company secures access to additional markets.
  • MarketBeat previews top five stocks to own in December.

PTC Therapeutics NASDAQ: PTCT expects to provide 2027 sales guidance for its oral phenylketonuria treatment Sephience in January, as executives seek to convince investors that the drug’s strong first year of sales can be sustained.

Speaking at the Jefferies Healthcare Conference in London, CEO Matt Klein said the company continues to see Sephience as a potential $2 billion-plus opportunity, though he stressed that figure is not official guidance and would take time to reach.

“We’re not going to guide to $2 billion next year,” Klein said, adding that the company expects steady U.S. growth and that its forthcoming guidance will reflect what it believes it can achieve.

Klein said PTC closed the third quarter with $182 million in revenue and more than $2.1 billion in cash. The company remains on track for its goal of reaching cash flow break-even in 2026, he said, positioning it to pursue sustainable profitability in 2027.

Launch Reaches More Than 2,000 Patients

About a year into the Sephience launch, more than 2,000 patients globally were on the drug, Klein said. PTC has launched it in the U.S., Europe and Japan and expects it to be available in more than 20 countries by year-end.

The company estimates that 17,000 people in the U.S. and 58,000 across the U.S. and other countries where it believes it can obtain access represent the potential patient population. Klein estimated that 14,000 to 15,000 U.S. patients had not yet tried Sephience.

Early in the launch, roughly two-thirds of patients had previously tried and failed another therapy, while approximately 20% to 25% were therapy-naive, Klein said. He estimated that 2,000 to 2,500 patients remained on Kuvan, another oral treatment, leaving room for additional switches.

Klein said PTC had received prescriptions from all U.S. centers of excellence by the second full quarter of the launch. He also pointed to social media and patient networks as ways people who were not regularly visiting clinics learned about the drug.

Jefferies analyst Faisal Khurshid asked whether the initial pace could be maintained. Klein acknowledged that prescribing can fluctuate around summer holidays and year-end closures but said the company expects continued U.S. growth.

International Access and Competition

Outside the U.S., Klein said PTC expects revenue in the fourth quarter to be roughly steady with the third quarter as it awaits access to additional markets. He expects new-market growth to come in 2027, although reimbursement discussions in Europe will take time.

Japan has had a strong start, Klein said. He expects another potential inflection after the first year following approval, when the required prescription renewal period expands beyond a month.

Asked about a kidney-directed therapy being developed by Otsuka, Klein said he had heard that potential approval could come in 2028 or later. He described the approach as potentially complementary to Sephience, while saying there was still more to learn about it.

Deal Strategy

CFO Pierre Gravier said PTC is looking for disciplined business-development opportunities that could use its global commercial infrastructure and accelerate growth. He said the company does not need to pursue deals simply to deploy capital.

Gravier described the agreement for Fabry disease gene therapy ST-920, which involved a $100 million upfront payment, as a distinctive opportunity rather than a sign that PTC plans to increase spending on early-stage gene therapy assets. Klein said the potential durability of the treatment and the cost of existing enzyme replacement therapy could support its commercial value.

About PTC Therapeutics (NASDAQ:PTCT)

PTC Therapeutics is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Founded in 1998 and headquartered in Warren, New Jersey, the company works across several therapeutic areas, including genetic and neurological disorders. Its products include Kebilidi (eladocagene exuparvovec), a gene therapy for aromatic L-amino acid decarboxylase deficiency, and Sephience (sepiapterin), a treatment for phenylketonuria. PTC has also developed medicines for Duchenne muscular dystrophy, including ataluren, marketed as Translarna in some regions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in PTC Therapeutics Right Now?

Before you consider PTC Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PTC Therapeutics wasn't on the list.

While PTC Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines